Immatics (IMTX) Cash from Discontinued Operations (2019 - 2024)
Immatics recorded quarterly Cash from Discontinued Operations of 37041845.6 in Q3 2024, down 11.47% quarter-over-quarter from 33230312.89 in Q3 2023, and down 11.47% year-over-year from 41841031.88 in Q4 2023.
Immatics' Cash from Discontinued Operations history runs 6 years deep, the most recent figure standing at 37041845.6 for Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -37.04 Mn |
| Sep 30, 2024 | -37.04 Mn |
| Sep 30, 2023 | -33.23 Mn |
| Sep 30, 2023 | -33.23 Mn |
| Sep 30, 2022 | -32.41 Bn |
| Sep 30, 2022 | -32.41 Bn |
| Jun 30, 2021 | 64.14 Bn |
| Jun 30, 2021 | 64.14 Bn |
| Mar 31, 2021 | -20.09 Bn |
| Mar 31, 2021 | -20.09 Bn |
| Sep 30, 2020 | -37.53 Bn |
| Sep 30, 2020 | -37.53 Bn |
| Jun 30, 2020 | -43.16 Bn |
| Jun 30, 2020 | -43.16 Bn |
| Mar 31, 2020 | 12.64 Bn |
| Mar 31, 2020 | 12.64 Bn |
| Sep 30, 2019 | 52.66 Bn |
| Sep 30, 2019 | 52.66 Bn |